173 related articles for article (PubMed ID: 34809510)
1. TYK2 inhibition: changing the treatment landscape for psoriasis?
Abduelmula A; Gooderham MJ
Expert Rev Clin Immunol; 2022 Mar; 18(3):185-187. PubMed ID: 34809510
[No Abstract] [Full Text] [Related]
2. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
3. Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.
Truong TM; Pathak GN; Singal A; Taranto V; Rao BK
Ann Pharmacother; 2024 Apr; 58(4):416-427. PubMed ID: 37341177
[TBL] [Abstract][Full Text] [Related]
4. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
Krueger JG; McInnes IB; Blauvelt A
J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
[TBL] [Abstract][Full Text] [Related]
6. Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.
Galluzzo M; Vellucci L; Marcelli L; Paganini C; Bianchi L; Talamonti M
Expert Opin Pharmacother; 2023 Jun; 24(9):981-988. PubMed ID: 37147879
[TBL] [Abstract][Full Text] [Related]
7. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis.
Gooderham MJ; Hong HC; Litvinov IV
Skin Therapy Lett; 2022 Nov; 27(6):1-5. PubMed ID: 36469536
[TBL] [Abstract][Full Text] [Related]
8. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).
Gonzalez Lopez de Turiso F; Guckian K
Expert Opin Ther Pat; 2022 Apr; 32(4):365-379. PubMed ID: 35001782
[TBL] [Abstract][Full Text] [Related]
9. TYK2 as a novel therapeutic target in psoriasis.
Elyoussfi S; Rane SS; Eyre S; Warren RB
Expert Rev Clin Pharmacol; 2023; 16(6):549-558. PubMed ID: 37287330
[TBL] [Abstract][Full Text] [Related]
10. Deucravacitinib in moderate-to-severe psoriasis.
Vu A; Maloney V; Gordon KB
Immunotherapy; 2022 Nov; 14(16):1279-1290. PubMed ID: 36373503
[TBL] [Abstract][Full Text] [Related]
11. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors.
Nogueira M; Puig L; Torres T
Drugs; 2020 Mar; 80(4):341-352. PubMed ID: 32020553
[TBL] [Abstract][Full Text] [Related]
12. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.
Rusiñol L; Puig L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834806
[TBL] [Abstract][Full Text] [Related]
13. Deucravacitinib: First Approval.
Hoy SM
Drugs; 2022 Nov; 82(17):1671-1679. PubMed ID: 36401743
[TBL] [Abstract][Full Text] [Related]
14. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.
Kingston P; Blauvelt A; Strober B; Armstrong AW
J Psoriasis Psoriatic Arthritis; 2023 Oct; 8(4):156-165. PubMed ID: 38188537
[TBL] [Abstract][Full Text] [Related]
15. Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.
Yarmolinsky J; Amos CI; Hung RJ; Moreno V; Burrows K; Smith-Byrne K; Atkins JR; Brennan P; ; McKay JD; Martin RM; Davey Smith G
Int J Cancer; 2022 Dec; 151(12):2155-2160. PubMed ID: 35747941
[TBL] [Abstract][Full Text] [Related]
16. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
Jensen LT; Attfield KE; Feldmann M; Fugger L
EBioMedicine; 2023 Nov; 97():104840. PubMed ID: 37863021
[TBL] [Abstract][Full Text] [Related]
17. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
Catlett IM; Hu Y; Gao L; Banerjee S; Gordon K; Krueger JG
J Allergy Clin Immunol; 2022 Jun; 149(6):2010-2020.e8. PubMed ID: 34767869
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
[TBL] [Abstract][Full Text] [Related]
19. TYK-ing all the boxes in psoriasis.
Schlapbach C; Conrad C
J Allergy Clin Immunol; 2022 Jun; 149(6):1936-1939. PubMed ID: 35341877
[No Abstract] [Full Text] [Related]
20. The preclinical discovery and development of deucravacitinib for the treatment of psoriasis.
Coscarella G; Malvaso D; Mannino M; Caldarola G; Fossati B; De Simone C; Chiricozzi A; Peris K
Expert Opin Drug Discov; 2023; 18(11):1201-1208. PubMed ID: 37574849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
